$JNJ · Johnson & Johnson

Johnson & Johnson filed a Form 3 initial statement of beneficial ownership for Thomas Cavanaugh, who is identified as Executive Vice President, Worldwide Chair, Innovative Medicine, effective September 1, 2026. The filing discloses his direct and indirect holdings in JNJ common stock: 71 shares held directly and 428 shares held indirectly through the Johnson & Johnson Savings Plan 401(k).

The filing also lists derivative securities. Cavanaugh holds seven employee stock option awards under the company’s Long-Term Incentive Plan, covering a total of 122,556 shares with exercise prices ranging from $151.41 to $243.45 and expiration dates between 2030 and 2036. In addition, he holds three restricted stock unit awards totaling 5,337 shares, which vest in three equal annual installments beginning on the first anniversary of each grant date. These disclosures are standard under Section 16 beneficial ownership reporting requirements.